12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Deals

ChemoCentryx, GlaxoSmithKline deal

ChemoCentryx said GlaxoSmithKline returned rights to CCX354, a CC chemokine receptor 1 (CCR1) antagonist that has completed Phase II testing for rheumatoid arthritis (RA). Last year, GSK exercised an option under a 2006 deal to license rights to CCX354, but...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >